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Abstract: 
Toxoplasma gondii is an obligate intracellular apicomplexan parasite that can infect a wide range of warm-blooded animals 
including humans. In humans and other intermediate hosts, toxoplasma develops into chronic infection that cannot be eliminated by 
host’s immune response or by currently used drugs. In most cases, chronic infections are largely asymptomatic unless the host 
becomes immune compromised. Thus, toxoplasma is a global health problem and the situation has become more precarious due to 
the advent of HIV infections and poor toleration of drugs used to treat toxoplasma infection, having severe side effects and also 
resistance have been developed to the current generation of drugs. The emergence of these drug resistant varieties of T. gondii has 
led to a search for novel drug targets. We have performed a comparative analysis of metabolic pathways of the host Homo sapiens 
and the pathogen T. gondii. The enzymes in the unique pathways of T. gondii, which do not show similarity to any protein from the 
host, represent attractive potential drug targets. We have listed out 11 such potential drug targets which are playing some 
important work in more than one pathway. Out of these, one important target is Glutamate dehydrogenase enzyme; it plays crucial 
part in oxidation reduction, metabolic process and amino acid metabolic process.  As this is also present in the targets of tropical 
diseases of TDR (Tropical disease related Drug) target database and no PDB and MODBASE 3D structural model is available, 
homology models for Glutamate dehydrogenase enzyme were generated using MODELLER9v6. The model was further explored 
for the molecular dynamics simulation study with GROMACS, virtual screening and docking studies with suitable inhibitors 
against the NCI diversity subset molecules from ZINC database, by using AutoDock-Vina. The best ten docking solutions were 
selected (ZINC01690699, ZINC17465979, ZINC17465983, ZINC18141294_03, ZINC05462670, ZINC01572309, ZINC18055497_01, 
ZINC18141294, ZINC05462674 and ZINC13152284_01). Further the Complexes were analyzed through LIGPLOT. On the basis of 
Complex scoring and binding ability it is deciphered that these NCI diversity set II compounds, specifically ZINC01690699 (as it 
has minimum energy score and one of the highest number of interactions with the active site residue), could be promising 
inhibitors for T. gondii using Glutamate dehydrogenase as Drug target. 
 
Key words: Homology modeling, Molecular dynamics, Docking, Metabolic Pathway Analysis, Glutamate dehydrogenase, 
Toxoplasma gondii, Structural biology, Drug targets, KEGG. 
 
 
Background: 
Toxoplasma gondii is an obligate intracellular 
Apicomplexan parasite that can infect a wide range of warm-
blooded animals including humans [1]. Toxoplasma  gondii was 
initially discovered by accident, in 1908, by a scientist, Charles 
Nicolle, who was working in North Africa and searching for a BIOINFORMATION  open access 
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reservoir of Leishmania in a native rodent, Ctenodactylus gundi. 
The  gundis  live  in  the foothills and mountains of Southern 
Tunisia and were commonly  used  to  study  Leishmania  at  
the  Pasteur Institute in Tunis. The name Toxoplasma means ‘arc 
form’ in  Greek  and  was  named  according  to  the  crescent- 
shaped  morphology  of  the  tachyzoite  and  bradyzoite stages 
of the organism observed by the scientists. At about the 
same time, Alfonso Splendore working in Sao Paulo discovered 
a similar parasite in rabbits. This pathogen is one of the most 
common in humans due to many contributing factors that 
include: (1) its complex life cycle allows it to be transmitted both 
sexually via felid fecal matter and asexually via carnivorism. 
(2)  Toxoplasma has an extremely wide host cell tropism that 
includes most nucleated cells. (3) In humans and other   
intermediate hosts, Toxoplasma develops into a chronic infection 
that cannot be eliminated by the host’s immune response or by 
currently used drugs. In most cases, chronic infections are 
largely asymptomatic unless the host becomes immune 
compromised. Together, these   
and other properties have allowed Toxoplasma to achieve infection 
rates that range from ~23% in the USA [2] to 50-70% in France 
[3]. 
 
There are two major reasons that new drugs are needed to treat 
Toxoplasma infections. First, the drugs currently used to treat 
Toxoplasma infections are poorly tolerated, have severe side 
effects, and cannot act against bradyzoites [4]. Second, there are 
reports that Toxoplasma is developing resistance to the current 
generation of drugs [5, 6]. How resistance to these drugs has 
developed is not known but is critical to understand because it 
will lead to improved drug design and will increase our 
understanding of the biological functions of these drug targets. 
One way to understanding mechanisms of resistance is to 
compare the transcriptional profiles of wild-type and resistant 
parasites grown in the absence or presence of the drug. Such 
studies in bacterial resistance have demonstrated that pathogen 
responses to antibiotics are multifactorial and complex [7]. 
Whether the same will be true in Toxoplasma is unclear, but data 
from these types of experiments will likely impact new anti-
Toxoplasma drug design. 
 
Over the last decade, complete genome sequences of several 
pathogens have been determined, and many more such projects 
are currently under way. While, these data potentially contain 
all the determinants of host-pathogen interactions and possible 
drug targets, Development of effective therapies for 
intracellular eukaryotic pathogens is a serious challenge, given 
the protected location of these pathogens and the similarity of 
their biology to that of the host [8].  Genomics approach can be 
applied to evaluate the suitability of potential targets using two 
criteria, i.e. "essentiality" and "selectivity" [9]. The target must be 
essential for the growth, replication, viability or survival of the 
microorganism, i.e. encoded by genes critical for pathogenic life-
stages. The microbial target for treatment should not have any 
well-conserved homolog in the host, in order to address 
cytotoxicity issues. This can  help  to  avoid  expensive  dead-
ends  when  a  lead  target  is  identified  and investigated in 
great detail only to discover at a later stage that all its inhibitors 
are invariably toxic to the host. Genes that are conserved in 
different genomes often turn out to be essential [10]. A gene is 
deemed to be essential if the cell cannot  tolerate  its   
inactivation  by  mutation,  and  its  status  is  confirmed  using 
conditional lethal mutants. Identifying cellular processes that are 
unique to the parasite is therefore a crucial step towards 
defining appropriate drug targets. Detection of genes that are 
non-homologous to human genes, and are essential for the 
survival of the pathogen represents a promising means of 
identifying novel drug targets [9]. 
  
 
Figure 1: A workflow for complete drug target identification 
using metabolic pathways analysis and molecular modeling, 
docking studies. 
 
We have performed a comparative analysis of metabolic 
pathways of the host Homo sapiens and the pathogen T. gondii. 
Enzymes from the biochemical pathways of T. gondii from the 
KEGG metabolic pathway database were compared with 
proteins from the host H. sapiens, by performing a BLASTp 
search against the non-redundant database restricted to the H. 
sapiens subset. Enzymes, which do not show similarity to any 
of the host proteins, below the threshold, were filtered out as 
potential drug targets [11].  The  T. gondii genes for the   
identified enzymes were also retrieved  for  BLASTP  search  to  
identify  any   homologous  protein  in  humans. We have listed 
out such potential drug targets which are playing some BIOINFORMATION  open access 
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important work in more than one pathway. Out of these, one 
important target is Glutamate dehydrogenase enzyme, which is 
having several activities like catalytic activity, oxidoreductase 
activity and binding activity. Glutamate dehydrogenase is also 
involved in oxidation process, metabolic process and amino 
acid metabolic process. During metabolic pathways analysis it 
was found that, it is a common enzyme in three metabolic 
pathways Alanine, Aspartate and Glutamate Metabolism, 
Arginine and Proline Metabolism and Nitrogen Metabolism. As 
this is also present in the targets of tropical diseases of TDR 
(Tropical disease related Drug) target database and no PDB and 
MODBASE 3D structural model is available. Thus, as a case 
study, we have built homology models and validated by using 
various online servers. The model was further explored for the 
molecular dynamics simulation study, virtual screening and 
molecular docking studies with suitable inhibitors. The three 
dimensional model of glutamate dehydrogenase presented here 
would be helpful in guiding both enzymatic studies as well as 
design of specific inhibitors. A complete drug target 
identification using metabolic pathways analysis and molecular 
modeling, docking studies workflow is followed in this work and 
given in Figure 1.    
 
Methodology: 
Identification of Unique Enzymes as Drug Targets 
Metabolic pathway information was obtained from the pathway 
database Kyoto Encyclopedia of Genes and Genomes. Enzyme 
commission numbers (EC) of the pathogen Toxoplasma gondii 
and the host H. sapiens were extracted from the KEGG database. 
Pathways unique to Toxoplasma gondii were filtered out. Out 
of total 84 metabolic pathways in humans 55 metabolic 
pathways were present in T. gondii. Out of these 55 metabolic 
pathways, 29 were such which contain unique enzymes 
which are only present in T. gondii and absent in humans 
(Table 1, see supplementary material). These are the pathways 
that do not appear in the host (H. sapiens) but are present in the 
pathogen. We further identified unique enzymes among shared 
pathways under carbohydrate metabolism, energy metabolism, 
lipid metabolism, nucleotide metabolism, amino acid metabolism, 
glycan biosynthesis and metabolism of co-factors and vitamins 
were obtained from the KEGG database. A total of 48 enzymes 
that are present in Toxoplasma gondii but absent in H. sapiens 
were obtained and their corresponding protein sequences 
were retrieved from the KEGG database. Out of these 48 enzymes, 
11 enzymes were commonly present in more than one pathway 
(Table 2, see supplementary material)  The protein sequences 
for these 48 unique enzymes were retrieved and were 
subjected to BLAST search against human protein sequences 
database at an expectation E-value cutoff of 10-2 to identify non-
homologous genes in Toxoplasma gondii.  Removing enzymes 
from the pathogen that share a similarity with the host protein 
ensures that the targets have nothing in common with the 
host proteins, thereby, eliminating undesired host protein-drug 
interactions [12]. The above search resulted in 48 enzymes that 
had “no hits” in BLAST search. Thirty of these 48 “no hits” 
belonged to the unique pathways set.  
 
Comparative Homology Modeling 
Out of the 11 enzymes, commonly present in more than one 
pathway, we have built a homology model of one of the 
potential drug target, Glutamate dehydrogenase enzyme (Gene 
I.D.: TGME49_093180 and EC No. is EC: 1.4.1.4.  
Template Selection and Model Building 
Template selection is a critical step in homology modeling. The 
amino acid sequence of NADP-specific glutamate 
dehydrogenase of Toxoplasma gondii ME49 (target) 
(XP_002370120.1) was retrieved from the protein database of 
National Center of Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/). The three-dimensional 
structure of the protein was not yet available in Protein Data 
Bank and Modbase Database. Also there is no expression 
information available for this gene; hence the present exercise of 
developing the 3D model of the glutamate dehydrogenase of 
Toxoplasma gondii was undertaken. BLASTP  search was 
performed against Brookhaven Protein Data Bank (PDB) with 
the default parameters to find suitable templates for homology 
modeling.  
 
The academic version of MODELLER9v6 
(http//:www.salilab.org/modeller), was used for 3D structure 
generation based on the information obtained from sequence 
alignment. The MODELLER software employs probability 
density functions (PDFs) as the spatial restraints rather than 
energy. The 3D model of a protein is obtained by optimization 
of the molecular pdf such that the model violates the input 
restraints as possible. The molecular pdf was derived as a 
combination of pdfs restraining individual spatial features of 
the whole molecule.  
 
Model Assessment and Refinement 
Out of 6 models generated, 5 by MODELLER and one by 
ModWeb server, the one with the best G-score of PROCHECK 
and with the best VERIFY3D profile was subjected to energy 
minimization. VERIFY3D (a structure evaluation server) was 
used to check the residue profiles of the obtained three- 
dimensional models. In order to assess the stereo-chemical 
qualities of the three dimensional models, PROCHECK analysis 
was performed. Quality evaluation of the model for the 
environment profile was also predicted using ERRAT structure 
evaluation server. The final refined model was evaluated for its 
atomic contacts using the Whatif program to identify bad 
packing of side chain atoms or unusual residue contacts. The 
predicted model was also analyzed for the recognition of errors 
in the three dimensional structure by using the ProSA web 
server.  This model was further subjected for identification of 
active site and docking study.  
 
With the aim of evaluating the stability and folding, 
conformational changes and getting insights into the natural 
dynamics on different timescale of protein in solution, 10 
nanoseconds (ns) molecular dynamics simulation were 
performed. The molecular dynamics (MD) simulations of 
modeled glutamate dehydrogenase protein were carried out 
with the GROMACS 4.0.6 software package by employing 
GROMOS 96 force field and the flexible SPC (Simple Point 
Charge) water model. The initial structure was immersed in a 
periodic water box of cubic shape (0.5 nm thick). Electrostatic 
energy was calculated using the particle mesh Ewald method. 
Cutoff distance for the calculation of the coulomb and van der 
Waals interaction was 1.0 Ǻ. After energy minimization using a 
steepest descent for 1000 steps, the system was subjected to 
equilibration at 300k and normal pressure for 100 ps under the 
conditions of position restraints for heavy atoms. LINCS 
constraints were performed for all bonds, keeping the whole BIOINFORMATION  open access 
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protein molecule fixed and allowing only the water molecule to 
move to equilibrate with respect to the protein structure. The 
system was coupled to the external bath by the Berendsen 
pressure and temperature coupling. The final MD calculations 
were performed for 10 ns under the same conditions except that 
the position restraints were removed. The results were analyzed 
using the standard software provided by the GROMACS 
package. An average structure was refined further using a 
steepest descent energy minimization. 
 
Binding Site Prediction 
Binding site was characterized by CASTp and PASS and 
compared by using the information of binding sites. By 
comparing prediction of above two algorithms, best active site 
was selected. 
 
Molecular Docking 
The docking of glutamate dehydrogenase was performed, 
against the NCI subset II molecules retrieved from ZINC 
database by using Autodock- vina (http://vina.scripps.edu/), 
where 1,364 molecules from the NCI diversity subset II 
(http://zinc.docking.org/index.shtml) were screened. The 
Python scripts in MGL tools package were used to analyze the 
docking results. 
 
Analyzing the Docking Results 
The search for the best ways to fit ligand molecules from the 
NCI diversity subset II, into glutamate dehydrogenase modeled 
structure, using Autodock- vina resulted in docking files that 
contained detailed records of docking. These log files were read 
into ADT (Auto Dock Tool) to analyze the results of docking. 
The similarity of docked structures was measured by 
computing the root mean square deviation (RMSD) between the 
coordinates of the atoms and creating clustering of the 
conformations based on the RMSD values. In most cases the 
first cluster was also the largest cluster found. The lowest 
binding energy conformation in the first cluster was considered 
as the most favorable docking pose. Binding energies that are 
reported represent the sum of the total intermolecular energy, 
total internal energy and torsional free energy minus the energy 
of the unbound system. The top ten ligands were selected based 
on the energy score after virtual screening Table 3 (see 
supplementary material) and were further analyzed by the 
program LIGPLOT. The Ligplot represents the hydrogen and 
hydrophobic interactions between ligand and active site 
residues. 
 
Discussion: 
Metabolic pathways analysis 
A total of 48 enzymes that are found present in Toxoplasma 
gondii  but absent in H. sapiens were listed out as potential 
drug targets. Out of these 48 enzymes, some are already reported 
in literature and often used as target in treatment of toxoplasmosis 
e.g. (i) Pyrimethamine is a competitive inhibitor of parasite 
DHFR with narrow (~ six-fold) selectivity for the T. gondii 
enzyme compared with the mammalian enzyme [13, 14], (ii) 
DHPS is the target of sulfa drugs [15 – 17], (iii) Acetyl-CoA, 
which mediates the formation of malonyl –CoA [18] etc.. 
 
Template search and Model Building 
Based on the maximum identity with high score and lower e-
value crystal structure of Glutamate dehydrogenase (NADP+) 
of Plasmodium falciparum (PDB code: 2bma_A) was selected as 
template. The sequence identity and similarity between the 
target and template are 58% and 73%, respectively. E- Value 
was 0.0. The sequence alignment of glutamase dehydrogenase 
of Toxoplasma gondii and Plasmodium falciparum was carried out 
using the CLUSTALW (http://www.ebi.ac.uk/clustalw/) 
program.  
 
 
Figure 2: Ribbon representation of modeled glutamate 
dehydrogenase protein. The a-helices & β-sheets are shown as 
helices and ribbons respectively & rest are shown as loops. 
(Pymol Model) 
 
Model Assessment and Refinement 
All the six glutamate dehydrogenase models obtained were 
validated by using the SAVS and PROSA server. 
Ramachandran plots were drawn and the structures were 
analyzed by PROCHECK, a well-known protein structure 
checking program. By comparison of the results for all the 
models second model was judged as best among six (Figure 2). 
I n  t h e  c a s e  o f  s e c o n d  m o d e l ,  i t  w a s  f o u n d  t h a t  t h e  p h i / p s i  
angles of 91.3% of the residues fell in the most favored regions, 
8.0% of the residues fell in the additional allowed regions, 0.7% 
fell in the generously allowed regions, and only 0.0 % of the 
residues fell in the disallowed regions. All these findings 
suggest a stereo-chemically very good model. The overall 
PROCHECK G factor for the homology-modeled structure was 
0.00. The energetic architecture as predicted by PROSA score 
was negative (-9.62) for the modeled protein. The value is close 
to that of template (-9.60), which indicates the reliability of the 
model. The final structure was validated by an ERRAT graph. 
The quality factor of 77.106 indicated good quality, as scores of 
>50 are acceptable for a reasonable model. High quality of 
model is also confirmed from VERIFY 3D server as 76.00% of 
residues of modeled protein showed a score higher than 0.02 
thus the model showed satisfactory 3D-1D scores for all the 
residues in the sequence. Results of WHAT_CHECK also 
indicate about the correctness of the modeled structure. These 
results indicate that the obtained structure has reasonably good 
quality. This model was used for virtual screening of the 
potential inhibitors for glutamate dehydrogenase. 
 
Molecular Dynamics Simulation 
The predicted Model of glutamate dehydrogenase has shown 
good accuracy of the structure. But in order to use this model BIOINFORMATION  open access 
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for virtual screening predicted model should have stable 
molecular dynamic behavior. The molecular dynamic stability 
has been established by performing the molecular dynamic 
simulation study using GROMACS 4.0.6 software package. The 
root mean square deviation (RMSD) during the simulation was 
increasing in the beginning but after 220 ps it becomes almost 
constant for rest of the duration of the simulation. This suggests 
that the glutamate dehydrogenase model has very less RMSD 
for the backbone and it also has less flexibility, indicating that 
model has a stable dynamic behavior structure. Molecular 
dynamic simulation study showed that the energy of the 
molecule was found to be constant throughout the time period 
of simulation. This suggests that the molecule has a stable 
structure as required for the virtual screening and drug 
designing. The root mean square (RMS) fluctuations were very 
less. Most the atoms were free from the RMS fluctuations. Very 
few atoms have shown RMS fluctuation at C and N terminal 
due to the loop region. This suggests the glutamate 
dehydrogenase model has an accurate and stable structure 
which can be used for virtual screening. The simulation studies 
also indicated that radius of gyration was increasing in the 
beginning but after 400 ps it decreases upto 420 ps and finally 
became almost constant for rest of the duration of the 
simulation. This suggests that the glutamate dehydrogenase 
model has a compact structure which provides the required 
stability to the molecule. 
 
Active Site Identification 
After getting the final model, the possible binding sites of 
modeled structure were searched using the CASTp server and 
PASS program. Ten possible binding sites were obtained. These 
sites were compared with active site of the template and it was 
found that pocket1 is highly conserved with the template. Since 
the glutamate dehydrogenase protein of Toxoplasma gondii and 
Plasmodium falciparum are well conserved in both sequence and 
structure, it is predicted that their biological function may be 
identical. From the structure-structure comparison of template 
and final refined models of glutamate dehydrogenase using 
SPDBV program, it was found that the residues in the site1 
Phe294, Pro295, Lys292, Gly293, Gly275, Ala272, Leu296, 
Ala276, Lys277, Arg417 and Asp421 are highly conserved 
within the active site of template. In this study, site1 is chosen 
as the binding site to dock with the NCI diversity set molecules. 
 
Virtual screening 
The top ten ligand molecules having minimum energy were 
screened out as the possible inhibitors for glutamate 
dehydrogenase [19] Table 3 (see supplementary material). All 
selected molecules were having energy score as follows: Ligand 
ZINC01690699 is having minimum energy score -9.1 Kcal/Mol. 
Ligand ZINC17465979 are having -8.1 Kcal/Mol. Four ligands, 
ZINC17465983, ZINC18141294_03, ZINC05462670 and 
ZINC01572309 are having energy score -7.9 Kcal/Mol, Four 
ligands, ZINC18055497_01, ZINC18141294, ZINC05462674 and 
ZINC13152284_01 are having energy score – 7.8. With the help 
of the Ligplot study we have selected ZINC01690699 as the 
possible inhibitor lead molecule, as it has minimum energy 
score and one of the highest number of interactions with the 
active site residue, it has 09 hydrophobic and 2 hydrogen 
interactions. Figure 3 (a) to (e), represent interactions of the top 
five ligands drawn by ligplot according to the energy score. 
 
Correlation coefficient analysis was performed between energy 
score calculated for all selected ligands molecules; log P value 
and molecular weight Table 3 (see supplementary material). 
The correlation coefficient is a statistical calculation that is used 
to examine the relationship between two sets of value. The 
Correlation coefficient between energy score and log P value 
was -0.101603358 and between energy score and molecular 
weight was -0.236816724. These values suggest a clear negative 
correlation between energy score of the ligands and their 
molecular weight and log P value. Thus the energy score of the 
ligands is independent of their molecular weight and log P 
value. The value of the correlation coefficient tells us about the 
strength and the nature of the relationship. Correlation 
coefficient values can range between +1.00 to -1.00. The 
negative correlation suggests that energy score may depend on 
interactions or the conformation of ligands and active site 
residues [20].  
  
 
Figure 3: Ligplot showing the protein-ligand interactions of top 
five ligands, based on energy score (hydrogen bonding and 
hydrophobic), generated by Ligplot program. (A) 
ZINC01690699; (B) ZINC17465979; (C) ZINC17465983; (D) 
ZINC18141294_03 and (E) ZINC05462670. 
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It was found the inhibitor ZINC01690699 has minimum energy 
score which reveals higher binding affinity towards the 
glutamate dehydrogenase and the inhibitor was also showing 
one of the best interactions with residues of the active site. The 
other important drug like properties like molecular weight and 
logP value were also found within the limits of drug like 
molecules.  For the wet laboratory validation of present study, 
samples of T. gondii can be collected from the pathological 
laboratories and the molecule ZINC01690699 can be procured 
from the Pubchem database. Growth inhibition of T. gondii by 
inhibitor ZINC01690699 can be established by the qualitative 
and quantities microbiological techniques. Thus, the three 
dimensional model of glutamate dehydrogenase presented here 
would be helpful in guiding both enzymatic studies as well as 
design of specific inhibitors. 
 
Conclusion: 
Our approach of comparative metabolic pathway analysis 
and molecular docking analysis resulted in the identification 
of potential drug targets. For the first time, the availability of 
complete genome sequences of many bacterial species is 
facilitating many novel computational approaches. The complete 
definition of all gene products by gene identification tools 
exemplified here is just the first step. The data presented here 
demonstrates that stepwise prioritization of genome open reading 
frames using simple biological criteria can be an effective way of 
rapidly reducing the number of genes of interest to an 
experimentally manageable number. This process is an 
efficient way for enriching p o t e nt ia l  t a r ge t  g e n e s,   a nd   f o r   
identifying  those  that  are  critical  for  normal  cell function.  
The  generation  of  a  comprehensive  essential  gene  list  will  
allow  an accelerated genetic dissection of traits such as metabolic 
flexibility and inherent drug resistance that render Toxoplasma 
gondii such a tenacious pathogen. Such a strategy will enable us 
to locate critical pathways and steps in pathogenesis; to target 
t h e s e  s t e p s  b y  d e s i g n i n g   n e w   d r u g s ;   a n d   t o   i n h i b i t   t h e    
infectious  agent  of  interest  with  new antimicrobial agents. 
Hence, in present study, it can be concluded that the molecule 
ZINC01690699 1-N, 4-N-bis [3-(1H-benzimidazol-2-yl) phenyl] 
benzene-1, 4-dicarboxamide has the potential to inhibit the 
growth of Toxoplasma gondii and can act as remedy for the 
treatment of Toxoplasma gondii infection.  
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Supplementary material: 
 
Table 1: Unique enzymes, which are only present in T. gondii and homologs are absent in humans. 
 S. 
No. 
Metabolic Pathway  Enzyme  Enzyme Detail  T. gondii Gene 
I.D. 
1.  Glycolysis  Gluconeogenesis  [EC:4.1.1.49]  Phosphoenolpyruvate carboxykinase   TGME49_089930 
2.  Citrate Cycle (TCA cycle)  [EC:4.1.1.49]  Phosphoenolpyruvate carboxykinase   TGME49_089650 
3.  Fatty Acid Biosynthesis  [EC:2.3.1.180] 
[EC: 4.2.1.-] 
[EC:1.3.1.9] 
 3-Oxoacyl-(acyl-carrier-protein) synthase III family protein;  
(3R)-Hydroxymyristoyl ACP dehydrase;   
Enoyl-acyl carrier reductase  
TGME49_031890 
TGME49_121570 
TGME49_051930 
4.  Oxidative Phosphorylation  [EC:1.6.99.3] 
[EC:3.6.3.6] 
Mitochondrial alternative NADH dehydrogenase 1; Pyridine 
nucleotide-disulphide oxidoreductase; Plasma-membrane H+-
ATPase  
TGME49_009150 
TGME49_088830 
TGME49_052640 
TGME49_084600 
5.  Purine Metabolism  (EC:3.2.1.3) 
[EC:2.7.7.4] 
SIN-like domain-containing protein;  
Sulfate adenylyltransferas-adenylylsulfate kinase 
TGME49_064460 
TGME49_082230 
6.  Pyrimidine Metabolism  [EC:3.5.2.3] 
(EC:3.2.1.3); 
[EC:2.1.1.451.5.
1.3] 
Dihydroorotase protein;  
SIN-like domain-containing protein; Bifunctional dihydrofolate 
reductase / thymidylate synthase  
TGME49_093610 
TGME49_064460 
TGME49_049180 
7.  Alanine, Aspartate and 
Glutamate Metabolism 
[EC:2.1.3.2] 
[EC:1.4.1.2] 
[EC:1.4.1.4] 
Aspartate carbamoyltransferase; NAD-specific glutamate 
dehydrogenase 
TGME49_091640 
TGME49_049390 
TGME49_093180 
8.  Glycine, Serine and 
Threonine Metabolism 
[EC:2.7.2.4] 
[EC:1.2.1.11] 
[EC:2.7.1.39] 
[EC:4.2.3.1] 
Aspartate kinase; Aspartate-semialdehyde dehydrogenase; 
Homoserine kinase; Threonine synthase 
TGME49_027090 
TGME49_005420 
TGME49_016640 
TGME49_020840 
9.  Cysteine and Methionine 
Metabolism 
[EC:2.5.1.47] 
[EC:2.1.1.10] 
[EC:2.7.2.4] 
[EC:1.2.1.11] 
[EC:2.3.1.31] 
O-acetylserine (thiol) lyase;  Cysteine synthase A; Homocysteine S-
methyltransferase-1; Aspartate kinase; Aspartate-semialdehyde 
dehydrogenase; Homoserine O-acetyltransferase 
TGME49_078910 
TGME49_057750 
TGME49_027090 
TGME49_005420 
TGME49_120730 
10.  Lysine Biosynthesis  [EC:2.7.2.4] 
[EC:1.2.1.11] 
Aspartate kinase; Aspartate-semialdehyde dehydrogenase  TGME49_027090 
TGME49_005420  
11.  Arginine and Proline 
Metabolism 
[EC:1.4.1.4]  NADP-specific glutamate dehydrogenase  TGME49_093180 
12.  Phenylalanine, Tyrosine and 
Tryptophan Biosynthesis 
[EC:4.2.3.5] 
[EC:2.5.1.54] 
Chorismate synthase; DAHP synthetase  TGME49_001380 
TGME49_021260 
13.  Beta-Alanine Metabolism   [EC:6.3.2.1]  Pantoate--beta-alanine ligase  TGME49_065870 
14.  Seleno-compound 
Metabolism 
[EC:2.7.7.4]  Sulfate adenylyltransferas-adenylylsulfate kinase  TGME49_082230 
15.  Starch and Sucrose 
Metabolism 
[EC:2.4.1.34] 
[EC:2.4.1.15] 
[EC:2.4.1.21] 
1,3-beta-glucan synthase; Trehalose-6-phosphate synthase domain-
containing protein; Glycogen synthase  
TGME49_078110 
TGME49_097720 
TGME49_022720 
16.  Amino Sugar and 
Nucleotide Sugar 
Metabolism 
[EC:2.7.7.64] UDP-N-acetylglucosamine  pyrophosphorylase    TGME49_018200 
17.  Glycosphingolipid 
Biosynthesis - globo series 
[EC: 2.3.1.-]  Acetyl-CoA transporter  TGME49_015940 
 
18.  Pyruvate Metabolism  [EC:4.4.1.5] 
[EC:4.1.1.49] 
Lactoylglutathione lyase; Phosphoenolpyruvate carboxykinase  TGME49_048400 
TGME49_089930 
TGME49_089650 
19.  Butanoate Metabolism  [EC:1.1.1.157]  3-Hydroxybutyryl-CoA dehydrogenase  TGME49_032090 
20.  Vitamin B6 Metabolism  [EC:2.7.1.35] 
[EC:4.2.3.1] 
[EC: 4.-.-.-] 
[EC: 2.6.-.-] 
Hypothetical protein; Threonine synthase;  
Ethylene inducible protein; Glutamine amidotransferase 
TGME49_097080 
TGME49_020840 
TGME49_037140 
TGME49_081490 
21.  Nicotinate and Nicotinamide 
Metabolism 
[EC:2.7.1.23] 
[EC:1.6.1.1] 
ATP-NAD kinase domain-containing protein; Transhydrogenase  TGME49_044700 
TGME49_118650 
22.  Pantothenate and CoA-
Biosynthesis 
[EC:6.3.2.1] Pantoate--beta-alanine  ligase    TGME49_065870 
23.  Lipoic acid Metabolism  [EC:2.7.7.63]  Lipoate-protein ligase A  TGME49_071820 
24.  Folate Biosynthesis  [EC:2.5.1.15] 
[EC:2.7.6.3] 
[EC:2.6.1.85] 
Hydroxymethyldihydropterin; Pyrophosphokinase-dihydropteroate 
synthase; Para-aminobenzoate synthase 
TGME49_059550 
TGME49_002920 
25.  Porphyrin and Chlorophyll 
Metabolism 
[EC:1.3.99.22] 
[EC:4.4.1.17] 
Radical SAM domain containing protein; Coproporphyrinogen III 
oxidase; Cytochrome c heme lyase;  
TGME49_088640 
TGME49_114040 BIOINFORMATION  open access 
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26.  Terpenoid Backbone 
Biosynthesis 
[EC:2.2.1.7] 
[EC:1.1.1.267] 
[EC:4.6.1.12] 
[EC:1.17.1.2] 
1-deoxy-D-xylulose 5-phosphate synthase;  
1-deoxy-D-xylulose 5-phosphate reductoisomerase; 2C-methyl-D-
erythritol 2; lytB domain-containing protein , Hydroxy-3-methylbut-
2-enyl diphosphate reductase  
TGME49_008820 
TGME49_014850 
TGME49_055690 
TGME49_027420 
27.  Nitrogen Metabolism  [EC:1.4.1.4]  NADP-specific glutamate dehydrogenase  TGME49_093180 
28.  Sulfur Metabolism  [EC:2.3.1.31] 
[EC:2.5.1.47] 
Homoserine O-acetyltransferase;  
O-acetylserine (thiol) lyase 
TGME49_120730 
TGME49_078910 
29.  Biosynthesis of Unsaturated 
Fatty Acids 
[EC:1.1.1.100] Oxoacyl-ACP  reductase  TGME49_017740 
 
Table 2: Enzymes, which are present in more than one pathway in T. gondii and absent   in humans. 
S. 
No. 
T. gondii Gene 
I.D. 
Enzyme Metabolic  Pathway  Function 
1.  TGME49_089930 Phosphoenolpyruvate 
Carboxykinase 
1. Glycolysis / 
Gluconeogenesis 
2. Pyruvate Metabolism 
Phosphoenolpyruvate carboxykinase (PEPCK) is an enzyme in the 
lyase family used in the metabolic pathway of gluconeogenesis. It 
converts oxaloacetate into phosphoenolpyruvate and carbon dioxide. 
2.  TGME49_089650 Phosphoenolpyruvate 
Carboxykinase 
1. Citrate cycle (TCA cycle) 
2. Pyruvate Metabolism 
Phosphoenolpyruvate carboxykinase (PEPCK) is an enzyme in the 
lyase family used in the metabolic pathway of gluconeogenesis. It 
converts oxaloacetate into phosphoenolpyruvate and carbon dioxide. 
3.  TGME49_093180 NAD-specific  glutamate 
dehydrogenase 
1. Alanine, Aspartate and 
Glutamate Metabolism 
2. Arginine and Proline 
Metabolism 
3. Nitrogen Metabolism 
(GLDH) is an enzyme, present in most microbes and the mitochondria 
of eukaryotes, required for  urea synthesis, that converts glutamate to 
α-Ketoglutarate, and vice versa.  
4.  TGME49_027090  Aspartate kinase  1. Glycine, Serine and 
threonine Metabolism 
2. Cysteine and Methionine 
Metabolism 
3. Lysine Biosynthesis 
Catalyzes the phosphorylation of the amino acid aspartate. This 
reaction is the first step in the biosynthesis of three essential amino 
acids: methionine, lysine, and threonine, known as the "aspartate 
family". 
5.  TGME49_005420 Aspartate-semialdehyde 
dehydrogenase 
1. Glycine, Serine and 
Threonine Metabolism 
2. Cysteine and Methionine 
Metabolism 
3. Lysine Biosynthesis 
It forms an early branch point in the metabolic pathway forming 
lysine, methionine, leucine and isoleucine from aspartate. This enzyme 
belongs to the family of oxidoreductases, specifically those acting on 
the aldehyde or oxo group of donor with NAD+ or NADP+ as 
acceptor.  
6.  TGME49_020840  Threonine synthase  1. Glycine, Serine and 
Threonine Metabolism 
2. Vitamin B6 Metabolism 
This enzyme belongs to the family of lyases, specifically those carbon-
oxygen lyases acting on phosphates. 
7.  TGME49_078910 O-acetylserine (thiol) lyase 1.  Cysteine and Methionine 
Metabolism 
2. Sulfur Metabolism 
The enzyme O-acetylserine (thiol)-lyase, using sulfide sources, 
converts O-acetylserine ester into cysteine, releasing acetate 
8.  TGME49_120730 Homoserine  O-
acetyltransferase 
1. Cysteine and Methionine 
Metabolism 
2. Sulfur Metabolism 
This enzyme belongs to the family of transferases, specifically 
those acyltransferases transferring groups other than aminoacyl 
groups. The two substrates of this enzyme are acetyl-CoA and L-
homoserine, whereas its two products are CoAand O-acetyl-L-
homoserine. 
9.  TGME49_065870 Pantoate--beta-alanine  ligase  1. Beta-Alanine Metabolism 
2. Pantothenate and CoA 
biosynthesis 
This enzyme belongs to the family of ligases, specifically those forming 
carbon-nitrogen bonds as acid-D-amino-acid ligases (peptide 
synthases). The 3 substrates of this enzyme are ATP, (R)- pantoate, 
and beta-alanine, whereas its 3 products are AMP,diphosphate, 
and (R)- pantothenate. 
10.  TGME49_082230 Sulfate  adenylyltransferas-
adenylylsulfate kinase 
1. Purine Metabolism 
2. Selenocompound 
Metabolism 
This enzyme belongs to the family of transferases, specifically those 
transferring phosphorus-containing nucleotide groups 
(nucleotidyltransferases). The two substrates of this enzyme 
are ATP and sulfate, whereas its two products are diphosphate and 
adenylyl sulfate. 
11.  TGME49_064460 SIN-like  domain-containing 
protein 
1. Purine Metabolism 
2. Pyrimidine Metabolism 
Utilizes a DNA template, i.e. the catalysis of DNA-template-directed 
extension of the 3'-end of an RNA strand by one nucleotide at a time. 
 
Table 3: Top ten ligand molecules identified from NCI diversity subset II of the ZINC database after virtual screening     
S. 
No. 
ZINC ID of the screened 
molecules 
Energy score 
(Kcal/Mol) 
No. of Hydrogen 
Interaction of ligand with 
active site residues 
No. Hydrophobic 
Interaction of ligand with active 
site residues 
Molecular Weight 
(g/mol) 
 
Log P 
value 
 
1. ZINC01690699  -9.1  2  9  548.59336 6.0 
2. ZINC17465979  -8.1    5  5  546.52144  5.9 
3. ZINC17465983  -7.9  4  5  546.52144 5.9 
4. ZINC18141294_03  -7.9  3  8  453.47264 5.3 
5. ZINC05462670  -7.9  4  5  546.52144  5.9 
6. ZINC01572309  -7.9  3  5  474.55802 5.0 
7. ZINC18055497_01  -7.8  1  7  479.67574  4.7 
8. ZINC18141294  -7.8  1  12  453.47264 5.3 
9. ZINC05462674  -7.8  4  6  546.52144  5.9 
10. ZINC13152284_01  -7.8  1  7  392.4492 6.7 
 
 